期刊
PEDIATRIC NEPHROLOGY
卷 34, 期 2, 页码 253-259出版社
SPRINGER
DOI: 10.1007/s00467-018-4052-x
关键词
Idiopathic nephrotic syndrome; Children; B cell; Rituximab
BackgroundSeveral studies have demonstrated that rituximab (RTX) improves relapse-free survival in patients with steroid-dependent nephrotic syndrome (SDNS). However, these studies used various RTX regimens and there are few data comparing these regimens in children with SDNS. In this retrospective study, we assessed the effect of three different initial RTX regimens on both time to B cell reconstitution and to first relapse.MethodsSixty-one SDNS patients receiving a first course of RTX were included. Group 1 received one injection of 100mg/m(2), group 2 received one injection of 375mg/m(2), and group 3 received two injections of 375mg/m(2) at day 0 and day 7. Time to B cell reconstitution and time to first relapse and respective risk factors were studied.ResultsMedian time to B cell reconstitution was 2.5 [1.8-3.5], 5.0 [3.9-6.0], and 6.6 [4.6-7.8] months in groups 1, 2, and 3, respectively. RTX regimen was associated with time to B cell reconstitution (HRs group 2 vs. 3, 4.07 [1.96-8.48]; group 1 vs. 3, 11.13 [4.04-30.67]). One-year relapse-free survival was 50% [58-77], 59% [42-76], and 72% [46-87] in groups 1, 2, and 3, respectively. RTX regimen was associated with risk of relapse (HRs group 2 vs. 3, 1.55 [0.51-4.65]; group 1 vs. 3, 4.98 [1.15-21.60]).ConclusionsThe initial dose of rituximab impacts time to B cell reconstitution and the probability of relapse. Risk of relapse is also associated with patient characteristics, suggesting that RTX regimen could be modified for each patient to balance efficacy, cost, and side effects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据